Three Potential Risk Genes for Bipolar Disorder: MT1E, MT1X and CX3CR1

Wei Jin¹, Ashley Chorath^{2*}, Shaolong Cao^{3*}

¹ Department of Neurology, Tongling People's Hospital, Tongling, 244000, China;

² Radiology and Imaging Sciences, National Institutes of Health Clinical Center, Bethesda, MD, 20892, USA;

³ Department of Bioinformatics & Computational Biology, UT MD Anderson Cancer Center, Houston, TX, 77030, USA.

*Corresponding to: Ashley Chorath, Radiology and Imaging Sciences, National Institutes of Health Clinical Center, Bethesda, MD, 20892, USA, Email: ashley.chorath@nih.gov; or Shaolong Cao, Department of Bioinformatics & Computational Biology, UT MD Anderson Cancer Center, 1400 Pressler Street, Houston, TX, USA, 77030. Email: scao@ mdanderson.org.

ABSTRACT

Background: Bipolar disorder (BP) is one of the most common mental illnesses, with the underlying mechanisms remaining unclear. The aim of this study is to investigate the novel genetic risk of BP by systematically reviewing published literature and performing a meta-analysis.

Method: A comprehensive search of electronic databases was completed using Illumina BioEngine. RNA expression data from brain tissue of 198 BP cases and 160 controls were analyzed, including six BP case/control bio-sets from four recent studies. The selected top BP risk genes were analyzed by integrating an online open source BP genetic database. Pathway enrichment analysis (PEA) and network connectivity analysis (NCA) were conducted to identify potential functional association between target genes and BP.

Results: Top three target genes were identified through the metaanalysis for BP, including MT1E, MT1X, and CX3CR1. These genes play roles within multiple BP genetic pathways and demonstrate solid connections with known BP target genes. NCA results also revealed a strong functional association between these genes and BP.

Conclusion: This study identified well-studied and novel BP target genes and their functional pathways that influence the BP pathogenesis. Our results may provide new insights into the understanding of the genetic mechanisms of BP.

Key Words: Bipolar disorder, ResNet Database, Pathway enrichment

JOURNAL OF PSYCHIATRY AND BRAIN SCIENCE



http://jpbs.qingres.com

OPEN ACCESS

DOI: 10.20900/jpbs.20170004 Received: January 20, 2017

Accepted: March 14, 2017

Published: April 25, 2017

Copyright: ©2017 Cain et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

analysis, Network connectivity analysis

1 INTRODUCTION

Bipolar disorder (BP) is one of the most common mental illnesses, characterized by recurrent episodes of mania and depression which affect thought, perception, emotions, and social behavior. As the sixth leading cause of disability in the world, BP affects approximately 1 % of the total population worldwide and about 3 % of people in US^[1]. Although the cause of BP remains unclear, it has been hypothesized that the genetic factors play important roles in the development of BP^[1, 2].

From the results of family studies, researchers found that compared to the general population, the risk of BP is four to ten times greater in first-degree relatives of a proband with BP^[3]. Additionally, the heritability study estimates for BP range between 60 % and 80 %^[4]. These studies suggest a substantial involvement of genetic factors in the development of the disorder. Furthermore, a large number of genetic studies of BP have been conducted to explore candidate genes for the disease. For example, BDNF, RELN and ANK3 were suggested as potential biomarkers for the disease ^[5-7]. Jang *et al.* found that the genetic dysfunction of Trpm2 causes uncontrolled phosphorylation of GSK-3, which may lead to the pathology of BP^[8].

Genome-wide association (GWA) studies identified multiple BP susceptibility loci ^[9]. Multiple modality genetic data from brain region samples were employed to identify BP genetic determinants^[10-13]. These previous studies built a solid background for BP genetic research, which could be leveraged for the discovery and evaluation of novel risk genes.

However, the risk estimates from individual studies often lack statistical power due to limited sample sizes and sample specificities in terms of phenotype characteristics. It is also difficult to draw a consistent conclusion as results are spread over a large number of independent studies. Therefore, a meta-analysis of multiple studies could provide a higher power assessment of the genetic risk factors of BP.

Based on four recent studies (2004 - 2012), a meta-analysis was performed for this study. Integrating a curated BP genetic database (BP_ Feb. 2017), the top genes from the meta-analysis were further analyzed. The BP_Feb. 2017 database was constructed using a large scale literature knowledge database, Pathway Studio (PS) ResNet database. In recent years, PS ResNet database has been widely used to study modeled relationships between proteins, genes, complexes, cells, tissues and diseases (http://pathwaystudio.gousinfo.com/ Mendeley.html). Our study identified novel BP risk genes and evaluated the effectiveness of integrating meta-analysis and PS ResNet database to identify and evaluate novel BP risk genes.

2 METHODS AND MATERIALS

2.1 Genetic data selection

A systematic search of electronic databases was conducted using Illumine BaseSpace Correlation Engine (http://www.illumina.com). Fig. 1 presents the diagram for the data selection. The 'Bipolar Disorder' search result identified 40 BP studies. Further filter criteria included: (1) the organism is Homo sapiens; (2) the data type is RNA expression; (3) the study is BP disease vs. normal control study (or includes case/control bio-sets); (4) the sample site is brain region. In total, six bio-sets (BP case/ control comparisons) from four studies satisfied the study selection criteria and were included in this systematic review and meta-analysis.



Fig. 1 Workflow diagram for meta-analysis data selection. Included criteria: (1) Organism is Homo sapiens; (2) Data type is RNA expression; (3) Study design is/includes BP disease vs. normal control biosets; (4) Sample site is brain region.

2.2 Genetic database BP_ Feb. 2017

The BP Feb. 2017 is a BP targeted knowledge database online available at 'Bioinformatics Database' (http://database.gousinfo.com/). The database is updated monthly or upon request. The current version of BP Feb. 2017 is composed of 535 BP target genes (BP Feb. 2017 \rightarrow Related Genes), 111 pathways (BP Feb.2017 \rightarrow Related Pathways), 115 related diseases (BP Feb. 2017 \rightarrow Related Diseases) and 202 related drugs (BP Feb. 2017 \rightarrow Related Drugs). The database also provides supporting references for each BP-Gene, including the titles and the sentences where the relation has been identified (see BP Feb. 2017 \rightarrow Ref for Related Genes). This information could be used to locate a detailed description of how a candidate gene or drug is related to BP.

With BP_Feb. 2017, further analysis of the BP target genes from the meta-analysis were conducted, including identifying their related BP pathways (BP_Feb. 2017 \rightarrow Related Pathways), genes (BP_Feb. 2017 \rightarrow Related Genes), and drugs (BP_Feb. 2017 \rightarrow Related Drugs). Here we defined two genes as functionally related if they play roles within the same genetic pathway. Pathway enrichment analysis (PEA) was conducted using Pathway Studio to identify genetic pathways potentially linked to BP^[14]. The gene-drug relationships were identified using the

network building module of Pathway Studio.

3 RESULTS

3.1 Selected Datasets

Screened by the selection criteria, six BP case/ control comparison bio-sets from four independent studies (GSE5392, GSE12649, GSE12654 and GSE35978) were retrieved and assessed for eligibility. Datasets GSE5392 was designed to study the pathophysiology of BP, suggests that dysregulation of the ubiguitin pathway and synaptic function may be central to the disease process ^[10]. GSE12649 suggests that mitochondrial dysfunction underlies the pathophysiology of BP^[11]. In GSE12654, by comparing the gene expression profiles of similar but distinctive mental disorders, researchers try to explore the uniqueness of bipolar disorder and its similarity to other mental disorders at the molecular level ^[12]. In datasets GSE35978, two co-expression modules were established in patients versus controls to detect the etiologies and pathological process of BP^[13]. Statistics of the included bio-sets are presented in Table 1.. Details about six BP case/control comparison bio-sets can be found in BP Meta \rightarrow Six bio-sets.

Table 1. Information	n of the four s	tudies where the	Meta-data were	originally used.
----------------------	-----------------	------------------	----------------	------------------

First Author	Design	Cases		Normal			Area	
T II'St Addition		n	Brain Region	Sources	n	Brain Region	Sources	
Iwamoto et al, 2004	Disease vs. Normal	11	Postmortem prefrontal cortex	RIKEN	15	Postmortem prefrontal cortex	RIKEN	Japan
lwamoto et al, 2005	Disease vs. Normal	33	Postmortem prefrontal cortex	RIKEN	34	Postmortem prefrontal cortex	RIKEN	Japan
Ryan et al, 2006	Disease vs. Normal	61 , 10	Dorsolateral prefrontal cortices from post-mortem brains;	University of Cambridge	11	Dorsolateral prefrontal cortices from post-mortem brains;	University of Cambridge	UK
		Orbitofrontal cortices from post-mortem brains			cortices from post- mortem brains			
Chen et al, 2012	Disease vs. Normal	e 37, cerebellum 46 ^{brain;} I parietal cortex brain	cerebellum brain;	Central South	50	cerebellum brain;	Central South	China
			University	50		University		

3.2 Meta-analysis results

The meta-analysis results were deposited into the 'Bioinformatics Database' (http://database.gousinfo. com), named BP_Meta. The top three genes (Score > 70) from the meta-analysis appear in Table 2., with more detailed statistics presented in BP_Meta \rightarrow Top Three Genes. The full meta-analysis results

are presented in BP_Meta \rightarrow Full Gene List. A gene's score is defined by the meta-analysis Illumina BaseSpace Correlation Engine (http://www.illumina. com), which represent the statistical significance and consistency of the gene across the queried bio-sets. The higher the score, the greater importance of the gene is for the case/control comparison.

Gene Correlation	EntrezGene ID	Score	Specificity	Associated Pathways	Gene Connectivity
MT1E	4493	100	6/6	perinuclear region of cytoplasm (0048471)	61
MT1X	4501	87	5/6	perinuclear region of cytoplasm (0048471)	61
CX3CR1	1524	72	4/6	Memory (0007613); neuron projection (0043005); perinuclear region of cytoplasm (0048471); signal transducer activity (0009369); GiCR (none); response to wounding (0009611)	193

Table 2. The top three genes of the included meta-analysis.

Score: A gene's score is based on the statistical significance and consistency of the gene across the queried bio-sets. **Specificity:** A gene's specificity is the number of bio-sets in which the direction of a gene's regulation matches the selected filter. **Associated Pathway:** The known BP related Pathways (BP_Meta \rightarrow Related Pathways) that contain the gene. GO ID is provided if any. **Gene Connectivity:** The number of known BP related genes (BP_Feb.2017 \rightarrow Related genes, BP_Meta \rightarrow Network Statistics) that connect with the target gene.

The top three genes were included in studies, but excluded from BP-gene relation data (MT1E, MT1X and CX3CR1). Further study using the BP_ Feb. 2017 showed that, these three genes were enriched within multiple BP target pathways and were connected to many other genes that were liked

to BP (see Table 2. BP_Meta \rightarrow Related Pathways). Fig. 2 (a) presents the functionally connections among these six pathways from three novel genes (MT1E, MT1X and CX3CR1); Fig. 2 (b) shows that connections between these three novel genes.



3.3 Network analysis

Additional functional network connectivity analysis (NCA) using PS showed that the three novel genes from this meta-analysis (MT1E, MT1X, CX3CR1) present strong functional association with BP. These

genes influence the pathogenic development of BP through multiple pathways, as shown in Figure 3. For each relation (arrow) in Fig. 3, there are at least one or more supporting references (see BP_Meta \rightarrow MT1E, MT1X and CX3CR1).



gousinfo.com/ResNetDatabase.html.

4 DISCUSSION

Although many genetic studies have been conducted to discover genetic risk factors for BP, combining the results from these separate studies in a metaanalysis could lead to a higher statistical power and more robust point estimate for the disease. In this study, meta-analysis was performed on six BP case/ control bio-sets extracted from four recent studies. The BP target genes from meta-analysis were sorted by gene score, which is based on the statistical significance and consistency of the gene across the queried bio-sets. Meta-analysis results suggested three top risk genes (MT1E, MT1X and CX3CR1) for BP (Score > 70), which are novel according to a recently updated database BP Feb. 2017. Further analyses were conducted to study the possible correlation between BP and these three genes, with more efforts focused on the two novel ones.

Results from PEA showed that these three novel genes are enriched within multiple BP pathways (BP Meta \rightarrow Related Pathways) and are linked to other BP genes (see Table 2. and Fig. 2). These results support the possible connection between these genes and BP. Besides, NCA results revealed multiple possible functional associations between BP and the three novel genes (see Fig. 3). For instance, MT1E could induce MMP9 activation ^[15], while MMP9 is suggested to be involved in the pathogenesis of BP disorder ^[16], which suggested MT1E could play a role in the development of BP through a MT1E \rightarrow MMP9 \rightarrow BP pathway. MT1X inhibits MT2A activation^[15]. MT2A can decrease the expression of proinflammatory cytokines in the brain such as TNF- $\alpha^{[17]}$, which play an importance role in the BP pathogenesis ^[18]. This suggests that MT1X plays a role in the disease-modifying therapy of BP through a MT1X \rightarrow MT2A \rightarrow TNF- $\alpha \rightarrow$ BP pathway. Lee et al. found that CX3CR1 deficiency reduced the levels of TNFα^[19]. Therefore, CX3CR1 may also be a potential target gene for BP. More potential regulation pathways could be identified from the BP_Meta database (BP_Meta \rightarrow MT1E, MT1X, and CX3CR1), which is available at 'Bioinformatics Database' (http://database.gousinfo.com).

It should be noted that, although the expression datasets were all acquired from human brain tissues, they were from different brain regions. Considering the functional variation of different brain regions, noise may be added to this meta-study leading to uncovered risk gene markers. Additionally, due to the limitation of the space, detailed discussion were focused on the most significant genes (Gene Score > 70). Genes with less significance from this metaanalysis may also poses potential linkage to BP. One could refer to the full gene list of 100 top genes of this meta-analysis, which is presented in the database BP_Meta.

In summation, despite some limitations, this meta-analysis revealed three novel potential risk genes for BP (MT1E, MT1X and CX3CR1). Further network analysis supported the meta-analysis results and identified possible functional pathways and mechanisms, thorough which these genes exert influence on BP. Findings in this study may provide new insights into the current field of BP genetic study.

CONFLICT OF INTERESTS

Authors claim no conflict of interests.

REFERENCES

- 1. Anderson IM, Haddad PM, Scott J. BP disorder. BMJ. 2012; 345: e8508.
- Goodwin GM. BP disorder. Medicine. 2013; 40(11): 596-598.
- Craddock N, Forty L. Genetics of affective (mood) disorders. Eur J Hum Genet. 2006; 14(6): 660-668.
- Nöthen MM, Nieratschker V, Cichon S, Rietschel M. New findings in the genetics of major psychoses. Dialogues Clin. Neurosci. 2010; 12: 85-93.
- Hashimoto K. Brain-derived neurotrophic factor (BDNF) and its precursor proBDNF as diagnostic biomarkers for major depressive disorder and bipolar disorder. Eur Arch Psychiatry Clin Neurosci. 2015; 265(1): 83-84.
- 6. Fatemi S. Cerebellum and autism. Cerebellum. 2013; 12(5): 778-779.
- Kato T, Hayashi-Takagi A, Toyota T, Yoshikawa T, Iwamoto K. Gene expression analysis in lymphoblastoid cells as a potential biomarker of bipolar disorder. J Hum Genet. 2011; 56(11): 779-783.
- Jang Y, Lee SH, Lee B, Jung S, Khalid A, Uchida K, Tominaga M, Jeon D, Oh U. TRPM2, a Susceptibility Gene for Bipolar Disorder, Regulates Glycogen Synthase Kinase-3 Activity in the Brain. J Neurosci. 2015; 35(34): 11811-11823.

- Mühleisen TW, Leber M, Schulze TG, Strohmaier J, Degenhardt F, Treutlein J, *et al.* Genome-wide association study reveals two new risk loci for bipolar disorder. Nat Commun. 2014; 5: 3339.
- Ryan MM, Lockstone HE, Huffaker SJ, Wayland MT, Webster MJ, Bahn S. Gene expression analysis of BP disorder reveals downregulation of the ubiquitin cycle and alterations in synaptic genes. Mol Psychiatry. 2006;11(10): 965-978.
- Iwamoto K, Bundo M, Kato T. Altered expression of mitochondria-related genes in postmortem brains of patients with BP disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. Hum Mol Genet. 2005; 14(2): 241-253.
- Iwamoto K, Kakiuchi C, Bundo M, Ikeda K, Kato T. Molecular characterization of BP disorder by comparing gene expression profiles of postmortem brains of major mental disorders. Mol Psychiatry. 2004; 9(4): 406-416.
- Chen C, Cheng L, Grennan K, Pibiri F, Zhang C, Badner JA, Members of the Bipolar Disorder Genome Study (BiGS) Consortium, Gershon ES, Liu C. Two gene co-expression modules differentiate psychotics and controls. Mol Psychiatry. 2013; 18(12): 1308-1314.
- Nikitin A, Egorov S, Daraselia N, Mazo I. Pathway studio--the analysis and navigation of molecular networks. Bioinformatics. 2003;

19(16): 2155-2157.

- Yamamoto T, Kudo M, Peng WX, Naito Z. Analysis of protein expression regulated by lumican in PANC-1 cells using shotgun proteomics. Oncol Rep. 2013; 30(4): 1609-1621.
- Samochowiec A, Grzywacz A, Kaczmarek L, Bienkowski P, Samochowiec J, Mierzejewski P, Preuss UW, Grochans E, Ciechanowicz A. Functional polymorphism of matrix metalloproteinase-9 (MMP-9) gene in alcohol dependence: family and case control study. Brain Res. 2010; 1327: 103-106.
- 17. Wiese L, Kurtzhals JA, Penkowa M. Neuronal apoptosis, metallothionein expression and proinflammatory responses during cerebral malaria in mice. Exp Neurol. 2006; 200(1): 216-226.
- Doganavsargil-Baysal O, Cinemre B, Aksoy UM, Akbas H, Metin O, Fettahoglu C, Gokmen Z, Davran F. Levels of TNF-α, soluble TNF receptors (sTNFR1, sTNFR2), and cognition in BP disorder. Hum Psychopharmacol. 2013; 28(2): 160-167.
- Lee S, Varvel NH, Konerth ME, Xu G, Cardona AE, Ransohoff RM, Lamb BT. CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models. Am J Pathol. 2010; 177(5): 2549-2562.